Journal article icon

Journal article

TB vaccine development: where are we and why is it so difficult?

Abstract:
The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either 'boost' a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.

Actions


Access Document


Authors


Wilkie, ME More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Journal:
Thorax
Publication date:
2014-11-05
DOI:
EISSN:
1468-3296
ISSN:
0040-6376
URN:
uuid:e9b60522-ff03-4a17-8116-f85cf382eeaa
Source identifiers:
491892
Local pid:
pubs:491892
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP